US20230158158A1 - Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 - Google Patents

Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 Download PDF

Info

Publication number
US20230158158A1
US20230158158A1 US17/914,545 US202117914545A US2023158158A1 US 20230158158 A1 US20230158158 A1 US 20230158158A1 US 202117914545 A US202117914545 A US 202117914545A US 2023158158 A1 US2023158158 A1 US 2023158158A1
Authority
US
United States
Prior art keywords
compound
plk1
mmol
ulm
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/914,545
Other languages
English (en)
Inventor
Si Woo CHOI
Soo Hee Ryu
Ji Hoon Ryu
San Ha SON
Hwa Jin LEE
Seong Hoon Kim
Boas NAM
Im Suk MIN
Hye Guk Ryu
Keum Young KANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uppthera Inc
Original Assignee
Uppthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uppthera Inc filed Critical Uppthera Inc
Assigned to UPPTHERA reassignment UPPTHERA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, SI WOO, MIN, Im Suk, KANG, Keum Young, KIM, SEONG HOON, LEE, HWA JIN, NAM, Boas, RYU, HYE GUK, RYU, JI HOON, RYU, Soo Hee, SON, San Ha
Publication of US20230158158A1 publication Critical patent/US20230158158A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Definitions

  • the present invention relates to a selective PLK1 degradation inducing compound, a method for preparing the same, and the use thereof.
  • Polo-like kinase 1 is a serine/threonine kinase involved in the conversion of G2/M phase during cell growth and division. PLK1 is expressed and activated in a pulse form from the S phase to the G2/M phase, and rapidly degrades as mitosis ends.
  • PLK1 is overexpressed in various carcinomas such as colon cancer, lung cancer, bladder cancer, and melanoma, etc., and cancer cells overexpressing PLK1 tend to show resistance to various types of anticancer drugs.
  • PLK1 inhibitor compounds such as volasertib (also known as BI6727), etc.
  • the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
  • the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
  • many pharmaceutical companies such as Boehringer Ingelheim, GlaxoSmithKline, etc., have attempted to develop small-molecular compound-based PLK1 inhibitors, but most of them have failed or stopped in the clinical trial stage, and thus there are no commercially available PLK1 inhibitors to date.
  • proteolysis targeting chimera has been proposed as a small molecule-based platform technology capable of inducing proteolysis of a target protein in the body.
  • the PROTAC is a bifunctional compound in which a ligand molecule that binds to disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker. Theoretically, the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase.
  • the PROTAC compound described in the above-described document is characterized by a compound that simultaneously degrades PLK1 and BRD4, and also induces the degradation of various proteins such as PLK family proteins other than PLK1 and BRD4, etc.), which may cause side effects due to off-target effects at the time of drug development.
  • PLK family proteins other than PLK1 and BRD4, etc.
  • the more effectively the PROTAC compound described in the above document degrades BRD4 the greater the clinical side effects are expected (see Bolden et al. Cell Reports, 2014).
  • the PROTAC compound which simultaneously degrades PLK1 and BRD4, has much stronger BRD4 degradation ability than PLK1 degradation ability at the cellular level, and the cell cycle thereof almost stops in the G1 phase, etc., that is, the PROTAC compound actually acts only as a BRD4 inhibitor regardless of the way that the conventional PLK1 inhibitors exert pharmacological effects.
  • An object of the present invention is to provide selective PLK1 degradation inducing compounds.
  • Another object of the present invention is to provide a method for preparing the compounds.
  • Still another object of the present invention is to provide a use of the compounds.
  • the present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation.
  • the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker.
  • ULM is CRBN or VHL E3 ubiquitin ligase binding moiety
  • PTM is PLK1 binding moiety represented by the following Formula II:
  • R 1 is hydrogen, C 1-4 alkyl or —(C 1-3 alkyl)-OH;
  • R 2 is —O—C 1-4 alkyl or —O—CF 3 ;
  • R 3 is N or CH
  • R4 is NH, N(C 1-3 alkyl), CH 2 or CH(C 1-3 alkyl) ⁇ ;
  • Linker is a chemical group that links ULM and PTM.
  • ULM is a CRBN E3 ubiquitin ligase binding moiety.
  • CRBN means Cereblon E3 ubiquitin ligase.
  • CRBN constitutes an E3 ubiquitin ligase complex together with DDB1, Cul4A and ROC1, wherein the CRBN is a substrate recognition subunit of the complex.
  • Some compounds capable of binding to the CRBN E3 ubiquitin ligase are known in the art. For example, after it was known that thalidomide binds to the CRBN E3 ubiquitin ligase (see Ito et al. 2010), it has been reported that a number of immunomodulatory imide drugs (IMiD) including lenalidomide and pomalidomide have CRBN binding ability (see Chamberlain and Brian. 2019; Akuffo et al. 2018; and Burslem et al. 2018, etc.).
  • IMD immunomodulatory imide drugs
  • the CRBN E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula A:
  • X 1 is —CH 2 —, —CH(C 1-4 alkyl)-, —CO— or —N ⁇ N—;
  • X 2 is hydrogen or C 1-3 alkyl
  • ULM is a VHL E3 ubiquitin ligase ligand binding moiety.
  • VHL means a von Hippel-Lindau tumor suppressor.
  • VHL constitutes a VCB E3 ligation complex together with Elongin B, Elongin C, CUL2 and Rbx1, wherein VHL is a substrate recognition subunit of the complex.
  • Some compounds capable of binding to the VHL E3 ubiquitin ligase are known in the art. For example, after it was known that peptide such as Ala-Leu-Ala-(Hy)Pro-Tyr-Ile-Pro heptapeptide (see Schneekloth et al. 2004) and Leu-Ala-(Hy)Pro-Tyr-Ile pentapeptide (see Rodriguez-Gonzalez et al.
  • VHL E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula B:
  • ⁇ circle around (H) ⁇ is 5-membered heteroaryl
  • Y 1 is hydrogen or C 1-3 alkyl
  • Formula B is represented by the moiety selected from the group consisting of:
  • the PTM a moiety that performs a target protein ligand function
  • PLK1 polo-like kinase 1
  • the compound represented by Formula II alone is a pyrazoloquinazoline derivative that may bind to the active site of PLK1 (see Valsasina, Barbara, et al. Molecular cancer therapeutics 11.4 (2012): 1006-1016. And WO2008/074788, etc.).
  • Formula II is represented by the following Formula III-1 or III-2.
  • R 1 , R 2 , R 3 and R 4 are the same as defined in Formula II.
  • R 1 is CH 3 .
  • R 2 is —OCH 3 or —OCF 3 .
  • R 3 is N.
  • R 4 is NH or N(C 1-2 alkyl).
  • Formula III-1 is represented by the following:
  • Formula III-2 is represented by the following:
  • the Linker as defined in Formula I is represented by the following Formula L:
  • L ULM is covalently bonded to ULM moiety through that is linked thereto,
  • L PTM is covalently bonded to PTM moiety through that is linked thereto,
  • L ULM and L PTM are each independently a single bond, —CH 2 —, —NH—, —O—, —CO—, —OCO—, —CONH— or —NHCO—,
  • L LNT is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CHCH—, —CC—, —CH 2 CH 2 O—, —OCH 2 CH 2 —, —CH 2 CH 2 S—, —SCH 2 CH 2 —, —COO—, —CONH—, —NHCO— and ⁇ circle around (L) ⁇ ⁇ wherein ⁇ circle around (L) ⁇ is 3-10 membered cycloalkyl, 4-10 membered heterocycloalkyl, 6-10 membered aryl, or 5-10 membered heteroaryl ⁇ ; and
  • p is an integer between 1 to 10.
  • Linker is a linker that is included in the compound selected from the group consisting of Compound 2 to 12.
  • the compound represented by Formula I is a compound that is selected from the group consisting of Compound 2 to 12.
  • a pharmaceutically acceptable salt refers to any organic or inorganic acid addition salt with a concentration that is relatively non-toxic, is harmless, and has effective action to patients, wherein side effects caused by this salt does not deteriorate beneficial efficacy of the compound represented by Formula I.
  • the pharmaceutically acceptable salt may be an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like, or an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid, but is not limited thereto.
  • an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like
  • an organic acid such as methanesulfonic acid, p-toluenesulf
  • the compound represented by Formula I above, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be prepared through reactions such as the following Reaction Schemes 1 to 3 by a synthetic method known in the field of organic chemistry or a modification technique apparent to those skilled in the art.
  • PTM, Linker and ULM are a group defined in the above, or a suitable derivative thereof.
  • RG 1 , RG 2 , RG 2a RG 2b , RG 3 , RG 3a , RG 3b and RG 4 are moieties including a suitable reactive group capable of linking together with an intermediate of the PROTAC compound represented by Formula I through formation of the covalent bond in the field of organic synthesis.
  • the formation of the covalent bond may be achieved by synthetic reactions such as amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation, and single bonds, double bond formation between various carbons, click chemistry and the like, depending on specific reaction groups, but is not limited thereto.
  • Variations of each step in the above Reaction Scheme may include one or multiple synthesis steps. Isolation and purification of the product may be accomplished by standard procedures known to those skilled in the art of organic chemistry.
  • the compounds of the present invention can be prepared through Reaction Scheme 2 by one or multiple synthetic steps.
  • the compound of the present invention may be prepared through the following reaction scheme.
  • the compound of the present invention may be prepared through the following reaction scheme.
  • RG 1 and RG 2 are L PTM or any reaction precursor thereof
  • RG3 and RG 4 are L ULM or any reaction precursor thereof
  • RG 1 , RG 2 , RG 3 and RG 4 may be appropriately selected according to the structure and linker position of the target compound.
  • RG 1 may be —COOH as shown in Examples
  • RG 1 may be hydrogen as shown in Examples 5-7.
  • each compound represented by PTM and ULM may be synthesized by a person skilled in the art with reference to documents known in the field of organic chemistry, descriptions of Examples of the present invention, and the like.
  • the present invention also provides the compounds represented by PTM-Linker-RG 3 or PTM-Linker 1-RG 2b that are the reaction intermediates of the compounds represented by Formula I.
  • An embodiment of the present invention is a composition for inducing PLK1 degradation including a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
  • the Formula I is the same as defined above.
  • the compounds of the present invention effectively induce the protein degradation of PLK1 ( FIG. 1 ).
  • the compounds of the present invention (Compounds 2-12) have significantly superior protein degradability of PLK1 compared to the compounds disclosed in CN 106543185 A, which is a prior art document.
  • the compounds of the present invention have little or no
  • the PLK1 degradation-inducing PROTAC compound of the present invention is capable of fundamentally degrading the target protein, PLK1 in view of the mechanism of action, thereby achieving an excellent PLK1 inhibitory effect as compared to the conventional PLK1 small molecule inhibitor that inhibits the simple activity of PLK1.
  • composition including the compound represented by Formula I of the present invention or a pharmaceutically acceptable salt thereof may be effectively employed for selective degradation of PLK1.
  • An embodiment of the present invention is a composition for preventing or treating PLK1-related diseases including the compound represented by Formula I or the pharmaceutically acceptable salt thereof.
  • An another embodiment of the present invention is a method for the prevention or treatment of PLK-related diseases comprising administering the composition to a subject in need thereof.
  • the Formula I is the same as defined above.
  • the PLK1-related disease refers to any disease or condition capable of being treated, alleviated, delayed, inhibited or prevented from induction of degradation or inhibition of activity of PLK1.
  • the PLK1-related disease may be a cancer (malignant tumor), a benign tumor, a neurological disease, or other genetic or non-genetic diseases caused by excessive cell division.
  • the cancer includes all cancers capable of exhibiting prophylactic or therapeutic efficacy due to inhibition of PLK1 activity, and may be solid cancer or blood cancer.
  • the cancer may be one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, skin cancer, skin or intraocular melanoma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer,
  • the benign tumors include all benign tumors capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, such as benign tumors in pre-cancer stages, and may be solid tumors or blood tumors.
  • the tumor may be one or more selected from the group consisting of Barrett's esophagus, colon adenoma and polyp, breast fibroadenoma and cyst, monoclonal gammopathy of undetermined significance (MGUS), monoclonal lymphocytosis, and the like, but is not limited thereto.
  • the neurological diseases include all neurological diseases capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, and specifically, may be one or more selected from the group consisting of central nervous system disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, senile dementia, epilepsy, Lou Gehrig, stroke, and nerve damage and axonal degeneration-related disorders following brain or spinal cord injury, but is not limited thereto.
  • the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar medicinal effects in addition to the compound represented by Formula I above, or the pharmaceutically acceptable salt thereof.
  • An embodiment of the present invention is a method of degrading PLK1 by administering a compound represented by Formula I or a pharmaceutically acceptable salt thereof to mammals including humans.
  • Another embodiment of the present invention is a method of degrading PLK1 by administering the compound represented by Formula I or the pharmaceutically acceptable salt thereof to a sample in vitro.
  • the sample may be a cell, a cell culture, a body fluid or tissue of a mammal including a human, but is not limited thereto.
  • the compound of the present invention exhibits an effect of inducing PLK1 degradation. Therefore, the pharmaceutical compound of the present invention may be effectively utilized for preventing or treating PLK1-related diseases.
  • FIG. 1 shows the western blotting results from the measurement of the protein degradability of PLK1 according to the bifunctional compound of the present invention.
  • the present invention provides synthetic methods for Compound 1 to 12 shown in the table below.
  • the compounds of the present invention were purified according to the following method and the structure was analyzed.
  • LCMS data were recorded with Shimadzu LCMS-2020 equipped with an electron spray ionization device. 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B) were used as mobile phases. As a column, Kinetex EVO C18 (2.1*30) mm, 5 um was used.
  • Step 1 Synthesis of benzyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (26)
  • Step 3 Synthesis of benzyl (2-(2-(2-(phenylamino)ethoxy)ethoxy)ethyl)carbamate (28)
  • Step 5 Synthesis of ethyl (Z)-6-((dimethylamino)methylene)-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (31)
  • Step 6 Synthesis of ethyl 8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate (32)
  • Step 8 Synthesis of methyl 3-bromo-5-iodo-2-methoxybenzoate (35)
  • Step 9 Synthesis of methyl 3-bromo-2-methoxy-5-(4-methylpiperazin-1-yl)benzoate (36)
  • the aqueous phase was extracted with EtOAc (500 mL ⁇ 2); the combined organic layer was washed with brine (400 mL), dried over Na 2 SO 4 , filtered, and concentrated under vacuum.
  • the combined organic layer was washed with brine and dried over Na 2 SO 4 , filtered.
  • the filtrate was concentrated under vacuum to afford the titled compound (13.15 g, 38.31 mmol, 74.81% yield) as yellow liquid.
  • Step 10 Synthesis of tert-butyl 3-bromo-2-methoxy-5-(4-methylpiperazin-1-yl)benzoate (37)
  • Step 11 Synthesis of ethyl 8-((3-(tert-butoxycarbonyl)-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate (38)
  • Step 12 Synthesis of 8-((3-(tert-butoxycarbonyl)-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (39)
  • Step 13 Synthesis of tert-butyl 3-((3-carbamoyl-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl)amino)-2-methoxy-5-(4-methylpiperazin-1-yl)benzoate (40)
  • Step 14 Synthesis of 3-((3-carbamoyl-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl)amino)-2-methoxy-5-(4-methylpiperazin-1-yl)benzoic acid (41)
  • Step 15 Synthesis of 8-((2-methoxy-5-(4-methylpiperazin-1-yl)-3-((2-(2-(2-(phenylamino)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (Compound 1)
  • prep-HPLC column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 11%-41%, 10 min
  • Step 1 Synthesis of (Z)-ethyl 6-((dimethylamino)methylene)-1-methyl-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (3)
  • Step 2 Synthesis of ethyl 8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate (4)
  • Step 3 Synthesis of tert-butyl 4-(3-bromo-4-(trifluoromethoxy)phenyl)piperazine-1-carboxylate (5)
  • Step 4 Synthesis of ethyl 8-((5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(trifluoromethoxy) phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate (6)
  • Step 5 Synthesis of 8-((5-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(trifluoromethoxy) phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • Step 6 Synthesis of tert-butyl 4-(3-((3-carbamoyl-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl)amino)-4-(trifluoromethoxy)phenyl)piperazine-1-carboxylate (8)
  • Step 7 Synthesis of 1-methyl-8-((5-(piperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (9)
  • Step 8 Synthesis of 8-((5-(4-(2-(2-(2-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (Compound 5)
  • Step 1 Synthesis of tert-butyl (2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)carbamate (43a)
  • Step 2 Synthesis of tert-butyl (2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamate (43b)
  • Step 3 Synthesis of tert-butyl ((S)-13-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-azapentadecyl)carbamate (43c)
  • Step 4 Synthesis of tert-butyl ((S)-16-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-14-oxo-3,6,9,12-tetraoxa-15-azaoctadecyl)carbamate (43d)
  • Step 5 Synthesis of (9H-fluoren-9-yl)methyl ((S)-19-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-20,20-dimethyl-17-oxo-3,6,9,12,15-pentaoxa-18-azahenicosyl)carbamate (43e)
  • Step 6 Synthesis of (2S,4R)-1-((S)-2-(2-(2-aminoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (44a)
  • Step 7 Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-aminoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (44b)
  • step 6 the tilted compound (330 mg, 539.06 umol, 42.86% yield, 100% purity, HCl salt) as a yellow oil was obtained.
  • Step 8 Synthesis of (2S,4R)-1-((S)-14-amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydr oxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (44c)
  • step 6 the tilted compound (660 mg, 975.57 umol, 54.02% yield, 97% purity, HCl salt) as a yellow oil was obtained.
  • Step 9 Synthesis of (2S,4R)-1-((S)-17-amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (44d)
  • step 6 the tilted compound (0.4 g, 0.57 mmol, 96.97% yield, HCl) as a yellow oil was obtained.
  • the crude product was used directly in the next step.
  • Step 10 Synthesis of (2S,4R)-1-((S)-20-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (44e)
  • Step 11 Synthesis of 8-((3-((2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)carbamoyl)-2-methoxy-5-(4-methylpiperazin-1-ylphenyl)amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (Compound 8)
  • the HeLa cell line was purchased from Korea Cell Line Bank (KCLB), Seoul, Korea. The passage in cell culture was maintained at P115 to P125.
  • cell counter (Thermo Fisher Scientific Inc., Catalog #AMQAX1000) and 0.4% trypan blue solution were used.
  • DMEM Gibco, Cat. No. 1195-65; Lot. No. 2085318
  • FBS Gibco, Cat. No. 16000-044; Lot. No. 2097593
  • PS Penicillin/Streptomycin
  • 100 mm 2 cell culture dish SPL, Cat. No. 20100
  • 150 mm 2 cell culture dish SPL, Cat. No. 20150
  • 12-well culture plate SPL, Cat. No. 30012
  • PBS pH 7.4 Gibco, Cat. No. 10010-023; Lot. No. 2085080
  • TrypLETM Express Gibco, Cat. No. 12605-010; Lot No. 2070638
  • Counting Chamber Hematocytometer
  • 0.4% Trypan Blue Solution DYNEBIO, Cat. No. CBT3710; Lot. No. 20190723
  • 2 ⁇ 10 5 cells were seeded for each well of a 12-well plate (SPL), and the cells were cultured in the culture medium in a total volume of 2 ml.
  • thymidine was completely dissolved in DW and used in the experiment.
  • thymidine block the products were treated with 2 mM of thymidine (Sigma-Aldrich Cat. No. T9250-5G) and then incubated for 24 hours.
  • the medium was suctioned and washed 3 times with 1 ⁇ PBS. Complete media was added, followed by incubation for 4 hours in a CO 2 incubator. Each compound was treated according to the concentration of 100 nM and then incubated for 6 hours again.
  • the cells were first separated from the plate using trypsin and then washed with the medium and PBS. Specifically, the medium was suctioned off and washed with 1 mL of PBS, and PBS was suctioned off. The cells were treated with 0.5 mL TrypLE Express at 37° C. for 7 minutes to separate the cells, and then 0.5 mL of complete medium was added to collect 1 mL of cell culture solution. Then, 1 mL of the cell collection solution was centrifuged at 8,000 rpm for 120 seconds, and the supernatant was removed. After washing with 0.2 mL of PBS, the PBS was removed.
  • a lysis buffer was added and cell debris was removed to obtain a cell lysate.
  • the cells were treated with 70 ⁇ L of 1 ⁇ RIPA buffer containing a protease inhibitor and incubated for 30 minutes on ice. Then, the cells were centrifuged at 4° C. and 15,000 rpm for 10 minutes to obtain a cell lysate.
  • SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
  • an image analyzer (GE) was used to obtain final blot data.
  • the ratio of PLK1 to GAPDH for each sample was calculated using the ImageQuant TL (ver. 8.2.0) program.
  • Each calculated value was entered into each cell of the Graphpad Prism 9 program, and the graph was automatically calculated to confirm the Dmax value corresponding to the protein degradation ability.
  • the compounds of the present invention exhibited PLK1 protein degradability (Dmax) of 40% or more.
  • Dmax of compounds 2, 3, 7, 9 were 60% or more, indicating excellent PLK1 protein degradability.
  • the compounds of the present invention have remarkably excellent PLK1 protein degradability compared with Comparative Compounds 1 and 2 described in CN106543185 A, and compared with the Example 1 compound in which an aniline group was connected by a linker ( FIG. 1 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
US17/914,545 2020-03-27 2021-03-27 Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 Pending US20230158158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200037875 2020-03-27
KR10-2020-0037875 2020-03-27
PCT/KR2021/003809 WO2021194320A1 (en) 2020-03-27 2021-03-27 Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1

Publications (1)

Publication Number Publication Date
US20230158158A1 true US20230158158A1 (en) 2023-05-25

Family

ID=77892014

Family Applications (5)

Application Number Title Priority Date Filing Date
US17/914,545 Pending US20230158158A1 (en) 2020-03-27 2021-03-27 Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
US17/914,574 Pending US20230203006A1 (en) 2020-03-27 2021-03-27 Vanillin derivative compounds inducing selective degradation of plk1
US17/914,565 Active 2042-09-20 US12403198B2 (en) 2020-03-27 2021-03-27 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1
US17/428,467 Active 2041-05-29 US11833208B2 (en) 2020-03-27 2021-03-27 PLK1 selective degradation inducing compound
US18/229,353 Abandoned US20230372498A1 (en) 2020-03-27 2023-08-02 Plk1 selective degradation inducing compound

Family Applications After (4)

Application Number Title Priority Date Filing Date
US17/914,574 Pending US20230203006A1 (en) 2020-03-27 2021-03-27 Vanillin derivative compounds inducing selective degradation of plk1
US17/914,565 Active 2042-09-20 US12403198B2 (en) 2020-03-27 2021-03-27 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1
US17/428,467 Active 2041-05-29 US11833208B2 (en) 2020-03-27 2021-03-27 PLK1 selective degradation inducing compound
US18/229,353 Abandoned US20230372498A1 (en) 2020-03-27 2023-08-02 Plk1 selective degradation inducing compound

Country Status (6)

Country Link
US (5) US20230158158A1 (enExample)
EP (1) EP3911654A4 (enExample)
JP (2) JP7440940B2 (enExample)
KR (8) KR20210122165A (enExample)
CN (1) CN113784969A (enExample)
WO (4) WO2021194318A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
WO2021194318A1 (en) * 2020-03-27 2021-09-30 Uppthera Plk1 selective degradation inducing compound
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
JP2024530495A (ja) * 2021-08-10 2024-08-21 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法
EP4446325A4 (en) * 2021-12-10 2025-04-16 Shandong Luye Pharmaceutical Co., Ltd. Protein kinase inhibitors, manufacturing processes therefor and use thereof
CN118339161B (zh) * 2021-12-10 2025-12-09 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
CN116924929A (zh) * 2022-07-08 2023-10-24 重庆圣华曦药业股份有限公司 一种碘比醇异构体的合成方法
CN115490675B (zh) * 2022-09-19 2024-11-12 安阳师范学院 季酮酸衍生物及其制备方法与应用
EP4626889A1 (en) * 2022-11-29 2025-10-08 Uppthera, Inc. Plk1 degradation inducing compounds with increased rigidity
WO2024153110A1 (zh) * 2023-01-17 2024-07-25 北京哲源科技有限责任公司 吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
KR20250037591A (ko) * 2023-02-02 2025-03-17 (주) 업테라 신규 plk1 분해 유도 화합물
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
KR20250058831A (ko) 2023-10-23 2025-05-02 주식회사 펩토이드 Ｐｌｋ－１의 폴로박스 도메인에 결합하는 저분자 화합물을 함유하는 항암제
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1937671T3 (da) * 2005-09-06 2010-04-26 Glaxosmithkline Llc Benzimidazolthiophenforbindelser som PLK-inhibitorer
SI2125822T1 (sl) * 2006-12-21 2015-01-30 Nerviano Medical Sciences S.R.L. Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze
KR101157848B1 (ko) * 2007-03-22 2012-07-11 다케다 야쿠힌 고교 가부시키가이샤 Ｐｌｋ１ 저해제로서 유용한 치환된 피리미도디아제핀
EA019487B1 (ru) * 2007-09-25 2014-04-30 Такеда Фармасьютикал Компани Лимитед Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
HK1208875A1 (en) 2012-01-12 2016-03-18 耶鲁大学 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
MX387318B (es) 2014-04-14 2025-03-18 Arvinas Operations Inc Moduladores de la proteólisis basados en imida y métodos de uso asociados.
CN108601764A (zh) 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
US20180147202A1 (en) * 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
US20170281784A1 (en) * 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
CN106543185B (zh) 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CA3050309A1 (en) * 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN106977584B (zh) * 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2019114770A1 (zh) * 2017-12-13 2019-06-20 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
KR102127289B1 (ko) * 2018-09-18 2020-06-26 고려대학교 산학협력단 암 세포를 표적화하기 위한 plk 선택적 형광 프로브 화합물 및 이를 포함하는 plk 검출용 형광 센서
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) * 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
WO2021194318A1 (en) * 2020-03-27 2021-09-30 Uppthera Plk1 selective degradation inducing compound
JP2024530495A (ja) * 2021-08-10 2024-08-21 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Beria, I. et al. Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors. J. Med. Chem. 2010, 53, 9, 3532–3551 (Year: 2010) *
Beria, I. et al. J. Med. Chem. 2010, 53, 9, 3532–3551 (Year: 2010) *
Cyrus et al. Impact of linker length on the activity of PROTACs. Mol. BioSyst., 2011, 7, 359-364 (Year: 2011) *
Mu, X. et al. Biochemical and Biophysical Research Communications, 2020, 521, 833e839 (Year: 2020) *
Mu, X. et al. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells. Biochemical and Biophysical Research Communications, 2020, 521, 833e839 (Year: 2020) *

Also Published As

Publication number Publication date
KR20210122165A (ko) 2021-10-08
US20230372498A1 (en) 2023-11-23
US11833208B2 (en) 2023-12-05
WO2021194319A1 (en) 2021-09-30
US20230159515A1 (en) 2023-05-25
WO2021194321A1 (en) 2021-09-30
EP3911654A4 (en) 2022-05-11
US20230104076A1 (en) 2023-04-06
US12403198B2 (en) 2025-09-02
KR102313752B1 (ko) 2021-10-19
KR20210150341A (ko) 2021-12-10
US20230203006A1 (en) 2023-06-29
KR102337029B1 (ko) 2021-12-09
EP3911654A1 (en) 2021-11-24
KR20210122164A (ko) 2021-10-08
KR102319264B1 (ko) 2021-11-01
KR20210122162A (ko) 2021-10-08
WO2021194320A1 (en) 2021-09-30
WO2021194318A1 (en) 2021-09-30
KR102313753B1 (ko) 2021-10-19
KR20210122163A (ko) 2021-10-08
KR102529222B1 (ko) 2023-05-08
JP2022539579A (ja) 2022-09-12
JP7440940B2 (ja) 2024-02-29
JP2023171659A (ja) 2023-12-01
CN113784969A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
US20230158158A1 (en) Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
US20220402907A1 (en) Modulators of proteolysis and associated methods of use
CN109311869B (zh) 通过细胞周期蛋白-依赖性激酶8(cdk8)抑制剂与e3连接酶配体的缀合降解cdk8和使用方法
ES2435779T3 (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
US20230219966A1 (en) Novel plk1 degradation inducing compound
US20210107868A1 (en) Derivatives of dolastatin 10 and auristatins
KR20150129010A (ko) Ido 억제제
WO2016014522A1 (en) Inhibitors of deubiquitinating proteases
US20230132823A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US12415797B2 (en) Heterocyclic compound as CDK-HDAC double-channel inhibitor
CN104203956A (zh) 用于治疗癌症的功能化的噻吩并吲哚衍生物
US20240317711A1 (en) Aurka selective degradation inducing compound
CN114401722A (zh) 酪氨酸激酶的抑制剂
US20240000951A1 (en) Gpx4 protein degradation-inducing compound
KR102574152B1 (ko) Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
CA3167646A1 (en) Imidazothienopyridine compounds and methods of use
KR102717168B1 (ko) 표적 단백질의 분해를 유도하기 위한 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 표적 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
US20160031838A1 (en) Smyd2 inhibitors
US11534439B2 (en) Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US20160152607A1 (en) Maleic acid derivative, production method for same, and anti-cancer composition comprising same
CN119462554A (zh) 一种hdac抑制剂及其制备、用途
JP2025540956A (ja) 硬直性が増加したｐｌｋ１分解誘導化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: UPPTHERA, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOI, SI WOO;RYU, SOO HEE;RYU, JI HOON;AND OTHERS;SIGNING DATES FROM 20220921 TO 20220922;REEL/FRAME:061218/0586

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER